I, of course appreciate you listing my recent posts on this forum, as most form a jerking circle here, whispering erotic predictions of 500- 1000% increase in share price, in the ear of the man in front!
I was just trying to warn you ‘ I care about GBM4 Patients, and not the money’ investors, that the DCVAX-L MAA is on target to get refused for these reasons..
1. Bastardised Clinical Trial Format.
2. Trial Duration.
3. Lack of Patient specific histology & genomic profiles.
4. Unverifiable trial data.
5. Price Point vs Patient / societal benefit.
There will be NO passage to Phase2 verification. The vaccine is on schedule to be killed off at the CHM.